StreetAlpha.app
Home › Stocks › LGND

Ligand Pharmaceuticals Inc (LGND)

Healthcare
$293.81
▼ −2.62%
LAST CLOSE · NOV 17

Ligand buys royalty rights in pharmaceutical products and earns income from its Captisol and NITRICIL technology platforms. It last closed at $293.81 on Nov 17, down 2.62% on the day. The average 12-month price target from 3 analysts is $369.67 (+25.8% from the last close), with a high of $402.00 and a low of $350.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is LGND in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$253.8M
+1.0% vs a year ago
Net income
$51.5M
+5.9% vs a year ago
EPS (diluted)
$2.49
+9.7% vs a year ago
Free cash flow
$90.6M
35.7% margin
Valuation
Market cap
$5.9B
20.0M shares
P/E
118.0
Price over 12 month EPS
Price to sales
23.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$56.0M
At Sep 30
Debt
$1.1B
At Sep 30
Shareholder equity
$961.8M
Buybacks
$60.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $241.5M$241.5MFY2021FY2022: $196.2M$196.2MFY2022FY2023: $131.3M$131.3MFY2023FY2024: $167.1M$167.1MFY2024FY2025: $268.1M$268.1MFY2025

From LGND's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on LGND in the past 90 days
Average 12-month target
$369.67
▲ 25.8% upside

Based on 3 analysts who set a price target on LGND in the past 90 days. The average target is $369.67, with a high of $402.00 and a low of $350.00, compared with the last close of $293.81.

Low $350.00Avg $369.67High $402.00
Blue marker: last close $293.81
Highest target$402.00
Average target$369.67
Lowest target$350.00
Latest rating changes
BarclaysTarget raised
Nov 11Buy$345 → $350
CitigroupTarget raised
Nov 5Buy$397 → $402
RBC CapitalTarget raised
Oct 30Buy$345 → $357
BarclaysInitiated
Sep 25Buy$345
CitigroupTarget raised
Sep 23Buy$387 → $397
DateFirmActionRatingPrice target
Nov 11BarclaysTarget raisedBuy$345 → $350
Nov 5CitigroupTarget raisedBuy$397 → $402
Oct 30RBC CapitalTarget raisedBuy$345 → $357
Sep 25BarclaysInitiatedBuy$345
Sep 23CitigroupTarget raisedBuy$387 → $397
Loading…

Technical Analysis

LGND · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 6% below its 20 day and 3% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 14) at $292.28, and the nearest resistance the swing high (Sep 11) at $294.00.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 3.8%/day
Key levels
$326.6352 week high+11.2%
$310.6320 day average+5.7%
$302.1350 day average+2.8%
$300.37Pivot R1+2.2%
$299.68100 day average+2.0%
$295.91Pivot+0.7%
$294.00Swing high (Sep 11)+0.1%
$293.81Last close
$292.28Swing low (Oct 14)−0.5%
$289.35Pivot S1−1.5%
$259.40200 day average−11.7%
$175.8952 week low−40.1%
Indicators
RSI (14)41.40Middle of its rangeNeutral
MACD0.54Below its signal lineBearish
Stochastic20.2Middle of its rangeNeutral
ADX (14)15.2No clear trend
Williams %R-93.2Oversold below −80, overbought above −20Oversold
CCI (20)-218.6Oversold below −100, overbought above 100Oversold
Rate of change−6.3%Change over 10 sessionsBearish
ATR (14)$11.19Typical daily range, 3.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for LGND

What happened before

See how LGND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LGND usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LGND has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LGND in the last 90 days.

Loading…

See today’s whale options flow across the market →

LGND Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●206 buying vs 191 selling
  • ▲Held by funds +1.9 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding432417+3.6%
In funds' top 101213−7.7%
Held by funds115.8%113.9%+1.9 pts
New / increased62 / 14494 / 150−15.6%
Reduced / sold out146 / 45111 / 37+29.1%
Put/call ratio0.520.39+32.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LGND institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LGND is in one of them and how their past LGND trades turned out.

LGND in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LGND in an article yet. Here's the latest on the wider market.

LGND Congress Trades

All congress trades →
Trades, 12 months
5
Buys
4
80%
Sells
1
20%
People
2
Last filed Jul 1
Who traded LGND · since 2020
Latest 5 filings of 7
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
$1K – $15KTraded May 29, 2026Filed Jun 8, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Jan 15, 2026Filed Feb 13, 2026
$1K – $15KTraded Jan 5, 2026Filed Feb 13, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d
Gilbert CisnerosD · CABuy$1K – $15KMay 29, 2026Jun 8, 202610 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KJan 15, 2026Feb 13, 202629 d
Gilbert CisnerosD · CABuy$1K – $15KJan 5, 2026Feb 13, 202639 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical royalty company based in San Diego, California. It buys and structures royalty interests in medicines that are in clinical development or already on the market, earning income from sales made by partner drugmakers. It also earns royalties and material sales from its Captisol and NITRICIL technology platforms. Its customers are mainly biopharmaceutical companies that develop and sell the medicines tied to its royalty streams.

Headquarters
San Diego, CA